Chandra  Vargeese net worth and biography

Chandra Vargeese Biography and Net Worth

Insider of WAVE Life Sciences

Dr. Chandra Vargeese joined Wave in 2014 as Senior Vice President and Head of Research and was named Chief Technology Officer in 2020. In this role, she is responsible for the advancement of Wave’s PRISM™ platform, which combines best-in-class oligonucleotide chemistry, multiple RNA-targeting modalities, and novel insights from human genetics. PRISM is foundational to all of Wave’s drug discovery and development efforts.

Chandra is one of the industry’s leading oligonucleotide chemists with approximately 30 years of oligonucleotide research experience. She has also authored numerous scientific publications and patents in the field.

Before joining Wave, Chandra worked at Novartis as Executive Director of Chemistry and Delivery, RNA Therapeutics Division for more than five years. Prior to joining Novartis, she led siRNA delivery in the RNA Therapeutics division at Merck & Co. Chandra joined Merck through its $1.1 billion acquisition of Sirna Therapeutics, where she was Vice President of Chemistry. Before her time at Sirna Therapeutics, she served as Associate Director of Chemistry at NeXstar Pharmaceuticals and is the co-inventor of Macugen® (pegaptanib), an approved therapy for treating wet AMD.

Chandra earned a PhD in organic chemistry at the Indian Institute of Science, Bangalore, India, and completed post-doctoral work at the University of Rhode Island.

What is Chandra Vargeese's net worth?

The estimated net worth of Chandra Vargeese is at least $5.18 million as of February 9th, 2026. Vargeese owns 408,246 shares of WAVE Life Sciences stock worth more than $5,176,559 as of February 14th. This net worth evaluation does not reflect any other assets that Vargeese may own. Additionally, Vargeese receives a salary of $731,800.00 as Insider at WAVE Life Sciences. Learn More about Chandra Vargeese's net worth.

How old is Chandra Vargeese?

Vargeese is currently 63 years old. There are 3 older executives and no younger executives at WAVE Life Sciences. Learn More on Chandra Vargeese's age.

What is Chandra Vargeese's salary?

As the Insider of WAVE Life Sciences Ltd., Vargeese earns $731,800.00 per year. The highest earning executive at WAVE Life Sciences is Dr. Paul B. Bolno M.B.A., M.D., President, CEO & Director, who commands a salary of $1,130,000.00 per year. Learn More on Chandra Vargeese's salary.

How do I contact Chandra Vargeese?

The corporate mailing address for Vargeese and other WAVE Life Sciences executives is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. WAVE Life Sciences can also be reached via phone at (656) 236-3388 and via email at [email protected]. Learn More on Chandra Vargeese's contact information.

Has Chandra Vargeese been buying or selling shares of WAVE Life Sciences?

During the past quarter, Chandra Vargeese has sold $43,416.60 in WAVE Life Sciences stock. Most recently, Chandra Vargeese sold 3,228 shares of the business's stock in a transaction on Monday, February 9th. The shares were sold at an average price of $13.45, for a transaction totalling $43,416.60. Following the completion of the sale, the insider now directly owns 408,246 shares of the company's stock, valued at $5,490,908.70. Learn More on Chandra Vargeese's trading history.

Who are WAVE Life Sciences' active insiders?

WAVE Life Sciences' insider roster includes Paul Bolno (CEO), Mark Corrigan (Director), Chris Francis (insider), Christian Henry (Director), Kyle Moran (CFO), Adrian Rawcliffe (Director), Ken Takanashi (Director), Chandra Vargeese (Insider), Gregory Verdine (Director), and Heidi Wagner (Director). Learn More on WAVE Life Sciences' active insiders.

Are insiders buying or selling shares of WAVE Life Sciences?

In the last twelve months, WAVE Life Sciences insiders bought shares 1 times. They purchased a total of 1,470,000 shares worth more than $27,930,000.00. In the last twelve months, insiders at the sold shares 21 times. They sold a total of 1,382,714 shares worth more than $18,073,723.90. The most recent insider tranaction occured on February, 9th when CFO Kyle Moran sold 3,588 shares worth more than $48,258.60. Insiders at WAVE Life Sciences own 24.0% of the company. Learn More about insider trades at WAVE Life Sciences.

Information on this page was last updated on 2/9/2026.

Chandra Vargeese Insider Trading History at WAVE Life Sciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/9/2026Sell3,228$13.45$43,416.60408,246View SEC Filing Icon  
2/16/2023Sell10,249$4.03$41,303.47106,624View SEC Filing Icon  
5/5/2022Sell16,714$1.72$28,748.08111,095View SEC Filing Icon  
2/16/2022Sell10,603$2.32$24,598.96View SEC Filing Icon  
2/18/2020Sell3,188$7.85$25,025.8037,057View SEC Filing Icon  
12/3/2019Sell6,000$32.34$194,040.00
9/24/2018Sell3,000$55.00$165,000.00View SEC Filing Icon  
1/23/2018Sell2,000$40.00$80,000.00View SEC Filing Icon  
11/22/2017Sell1,500$35.00$52,500.00View SEC Filing Icon  
See Full Table

Chandra Vargeese Buying and Selling Activity at WAVE Life Sciences

This chart shows Chandra Vargeese's buying and selling at WAVE Life Sciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

WAVE Life Sciences Company Overview

WAVE Life Sciences logo
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
Read More

Today's Range

Now: $12.68
Low: $12.54
High: $13.16

50 Day Range

MA: $15.20
Low: $12.68
High: $21.31

2 Week Range

Now: $12.68
Low: $5.28
High: $21.73

Volume

2,235,107 shs

Average Volume

3,113,218 shs

Market Capitalization

$2.12 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A